Summary of Key Information:
Reporting Period (Quarter/Year): First Quarter ended June 30, 2026 (Q1 FY26)
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 of SEBI (LODR) Regulations, 2015
Audit Opinion:
Clean - Limited Review Report with Emphasis of Matter regarding GST disputes
Key Financial Highlights [₹ Lakhs]:
Standalone Results:
Revenue from Operations: ₹2,658.32 (Q1 FY26) vs ₹3,462.40 (Q1 FY25) - 23.2% decrease YoY
Total Income: ₹2,849.42 (Q1 FY26) vs ₹3,521.96 (Q1 FY25) - 19.1% decrease YoY
Net Profit: ₹7.51 (Q1 FY26) vs ₹338.89 (Q1 FY25) - 97.8% decrease YoY
EPS: ₹0.03 (Basic and Diluted) vs ₹1.43 (Q1 FY25)
Other Equity: ₹2,365.63
Quarterly Comparison:
| Particulars | 30th June 2026 | 31st March 2026 | 30th June 2025 |
| Revenue from Operations | 2,658.32 | 4,223.93 | 3,462.40 |
| Other Income | 191.10 | 176.16 | 59.56 |
| Total Income | 2,849.42 | 4,400.09 | 3,521.96 |
| Total Expenses | 2,841.91 | 4,138.14 | 3,183.07 |
| Net Profit | 7.51 | 274.91 | 338.89 |
| EPS (₹) | 0.03 | 1.16 | 1.43 |
Expense Breakdown [₹ Lakhs]:
Cost of Material Consumed: ₹1,431.50
Manufacturing Expenses: ₹488.75
Change in Inventories: (₹170.44) [negative indicates decrease]
Employee benefits expenses: ₹561.63
Finance cost: ₹93.70
Depreciation and Amortization: ₹178.07
Other expenses: ₹258.70
Segment-wise Performance:
The company operates in only one segment: manufacturing of pharmaceutical formulations as per Ind AS 108.
Corporate Actions:
Annual General Meeting: The 31st AGM will be held on Friday, September 11, 2026, at 10:00 AM IST through Video Conferencing/Other Audio-Visual Means.
Book Closure: The Register of Members and Share Transfer Books will remain closed from Saturday, September 5, 2026 to Friday, September 11, 2026 (both days inclusive).
Cut-Off Date: The eligibility date for voting at the 31st AGM is Friday, September 4, 2026.
Other Significant Information:
The financial results have been prepared in accordance with Ind AS 34 (Interim Financial Reporting).
Figures for quarter ended 31st March 2026 are balancing figures between audited annual figures and published unaudited nine-month figures.